Biocon, Mylan win US court ruling in favour of insulin Glargine

US District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan ’s insulin Glargine product ‘not infringed’ and ‘invalid’ for lack of written description, said Biocon in a press statement. Semglee is co-developed with Mylan in the US.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news